Reuters logo
BRIEF-Genmab to present seven abstracts at annual ASCO meeting
April 20, 2017 / 2:21 PM / 8 months ago

BRIEF-Genmab to present seven abstracts at annual ASCO meeting

April 20 (Reuters) - Danish biotech company Genmab

* Says seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6

* Says the abstracts were submitted by collaboration partner, Janssen Biotech, Inc.

* Says the abstracts include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation

* Says descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting Source text for Eikon: Further company coverage: (Copenhagen newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below